Regeneron's Manufacturing Missteps Lead to FDA Rejection and Stock Slump
The US Food and Drug Administration (FDA) rejected Regeneron Pharmaceuticals' application for a stronger formulation of its eye medicine Eylea due to ongoing inspection findings at a Catalent Inc. production facility in Bloomington, Indiana. Catalent confirmed that its facility was the one in question and stated that it is taking the observations seriously and working on proposed corrective actions. This is the latest setback for Catalent, which has faced previous inspection-related issues impacting the supply of Moderna's Covid booster shot and Novo Nordisk's weight-loss drug Wegovy. The delay in approval could be costly for Regeneron, as it faces potential competition from cheaper versions of Eylea next year.
- Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep Yahoo Finance
- Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups FiercePharma
- Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release Barron's
- REGN Stock Crumbles After The FDA Rejects Its Next Possible Blockbuster Investor's Business Daily
- Pharmalittle: FDA declines to approve higher dose version of Regeneron eye drug; FDA warns wholesaler over counterfeit HIV pills STAT
Want the full story? Read the original reporting
Read on Yahoo Finance